Leading R&D Ventures and Digital Biology at IFF, building a global portfolio of TechBio platforms from discovery through commercialization. I focus on scaling AI‑enabled biology where industrial reality matters, linking prediction to manufacturing to deliver revenue acceleration, margin expansion, and access to novel molecules previously impossible to produce at scale.

I lead the evolution of IFF’s Lab‑in‑a‑Loop platform, integrating AI, protein engineering, and bioprocessing to translate breakthrough science into durable businesses. My role spans platform strategy, external partnerships, and strategic M&A, acquiring critical AI/ML, synthetic biology, talent, and manufacturing capabilities. Core thesis: biology only scales when economics, sustainability, and user value align.

Previously, I led global enzyme, strain, and bioprocess programs across four continents, delivering 40+ technology transfers and 13 commercial products, including one of the highest‑tonnage engineered enzymes ever commercialized. I also led the enzyme platform for the $225M DuPont cellulosic ethanol FOAK biorefinery.

I advise startups, investors, and U.S. government and National Labs. PhD in Biochemical Engineering (UC Berkeley), Harvard Business School alumnus, 36 patents, JBEI Board member, and UC Berkeley guest lecturer.